{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:07:01Z","timestamp":1771258021178,"version":"3.50.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.medcli.2025.106939","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T11:42:41Z","timestamp":1745235761000},"page":"106939","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Biomarcadores en amiloidosis por transtirretina. Presente y futuro"],"prefix":"10.1016","volume":"164","author":[{"given":"Fernando","family":"Mart\u00ednez Valle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"P\u00e9rez Bocanegra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2025.106939_bib0330","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.beha.2005.01.030","article-title":"Amyloidosis","volume":"18","author":"Gertz","year":"2005","journal-title":"Best Pract Res Clin Haematol."},{"key":"10.1016\/j.medcli.2025.106939_bib0335","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s004280050471","article-title":"Highly sensitive diagnosis of amyloid and various amyloid syndromes using Congo red fluorescence","volume":"436","author":"Linke","year":"2000","journal-title":"Virchows Arch."},{"key":"10.1016\/j.medcli.2025.106939_bib0340","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jns.12153","article-title":"Red-flag symptom clusters in transthyretin familial amyloid polyneuropathy","volume":"21","author":"Concei\u00e7\u00e3o","year":"2016","journal-title":"J Peripher Nerv Syst."},{"key":"10.1016\/j.medcli.2025.106939_bib0345","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11897-022-00570-1","article-title":"Update on disease-specific biomarkers in transthyretin cardiac amyloidosis","volume":"19","author":"Hood","year":"2022","journal-title":"Curr Heart Fail Rep."},{"key":"10.1016\/j.medcli.2025.106939_bib0350","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1185\/03007995.2012.754348","article-title":"THAOS-The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis","volume":"29","author":"Coelho","year":"2013","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.medcli.2025.106939_bib0355","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation."},{"key":"10.1016\/j.medcli.2025.106939_bib0360","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/ejhf.2113","article-title":"Use of biomarkers to diagnose and manage cardiac amyloidosis","volume":"23","author":"Castiglione","year":"2021","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.medcli.2025.106939_bib0365","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1161\/CIRCULATIONAHA.104.482570","article-title":"Biomarkers of cardiovascular disease: Molecular basis and practical considerations","volume":"113","author":"Vasan","year":"2006","journal-title":"Circulation."},{"key":"10.1016\/j.medcli.2025.106939_bib0370","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s11739-022-02958-2","article-title":"Circulating biomarkers in diagnosis and management of cardiac amyloidosis: A review for internist","volume":"17","author":"Perfetto","year":"2022","journal-title":"Intern Emerg Med [Internet]."},{"key":"10.1016\/j.medcli.2025.106939_bib0655","first-page":"709","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC: Heart Failure."},{"key":"10.1016\/j.medcli.2025.106939_bib0380","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","article-title":"Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis","volume":"107","author":"Palladini","year":"2003","journal-title":"Circulation."},{"key":"10.1016\/j.medcli.2025.106939_bib0385","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3324\/haematol.2011.040493","article-title":"Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis","volume":"96","author":"Wechalekar","year":"2011","journal-title":"Haematologica."},{"key":"10.1016\/j.medcli.2025.106939_bib0660","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/asheducation.V2012.1.595.3798563","article-title":"Differential diagnosis of monoclonal gammopathy of undetermined significance","volume":"2012","author":"Merlini","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"10.1016\/j.medcli.2025.106939_bib0395","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol [Internet]."},{"key":"10.1016\/j.medcli.2025.106939_bib0400","doi-asserted-by":"crossref","first-page":"810","DOI":"10.2459\/JCM.0000000000000349","article-title":"Different NT-proBNP circulating levels for different types of cardiac amyloidosis","volume":"17","author":"Perfetto","year":"2016","journal-title":"J Cardiovasc Med (Hagerstown)."},{"key":"10.1016\/j.medcli.2025.106939_bib0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0173086","article-title":"Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis-Report from the Transthyretin Amyloidosis Outcome Survey (THAOS)","volume":"12","author":"Kristen","year":"2017","journal-title":"PLoS One."},{"key":"10.1016\/j.medcli.2025.106939_bib0410","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/clc.22353","article-title":"Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis","volume":"38","author":"Cappelli","year":"2015","journal-title":"Clin Cardiol."},{"key":"10.1016\/j.medcli.2025.106939_bib0415","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.21037\/jtd.2018.07.56","article-title":"Value of cardiac biomarker measurement in the differential diagnosis of infiltrative cardiomyopathy patients with preserved left ventricular systolic function","volume":"10","author":"Hu","year":"2018","journal-title":"J Thorac Dis."},{"key":"10.1016\/j.medcli.2025.106939_bib0665","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1177\/2047487319877708","article-title":"Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings","volume":"27","author":"Vergaro","year":"2020","journal-title":"Eur J Prev Cardiol."},{"key":"10.1016\/j.medcli.2025.106939_bib0425","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.medcli.2025.106939_bib0430","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.medcli.2025.106939_bib0435","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","article-title":"Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness","volume":"37","author":"Damy","year":"2016","journal-title":"Eur Heart J."},{"key":"10.1016\/j.medcli.2025.106939_bib0670","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J."},{"key":"10.1016\/j.medcli.2025.106939_bib0445","first-page":"73","article-title":"Markers of nutritional status and inflammation in transthyretin cardiac amyloidosis: Association with outcomes and the clinical phenotype","volume":"27","author":"Driggin","year":"2020","journal-title":"Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis."},{"key":"10.1016\/j.medcli.2025.106939_bib0450","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jaccao.2020.01.006","article-title":"Plasma hepatocyte growth factor for diagnosis and prognosis in light chain and transthyretin cardiac amyloidosis","volume":"2","author":"Zhang","year":"2020","journal-title":"JACC CardioOncology."},{"key":"10.1016\/j.medcli.2025.106939_bib0455","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation."},{"key":"10.1016\/j.medcli.2025.106939_bib0460","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s11739-020-02474-1","article-title":"Poor right ventricular function is associated with impaired exercise capacity and ventilatory efficiency in transthyretin cardiac amyloid patients","volume":"16","author":"Bartolini","year":"2021","journal-title":"Intern Emerg Med."},{"key":"10.1016\/j.medcli.2025.106939_bib0465","first-page":"187","article-title":"Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: New evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis","volume":"16","author":"Lehrke","year":"2009","journal-title":"Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis."},{"key":"10.1016\/j.medcli.2025.106939_bib0470","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.medcli.2025.106939_bib0475","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J."},{"key":"10.1016\/j.medcli.2025.106939_bib0480","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.cjca.2019.12.020","article-title":"Biomarkers and prediction of prognosis in transthyretin-related cardiac amyloidosis: direct comparison of two staging systems","volume":"36","author":"Cappelli","year":"2020","journal-title":"Can J Cardiol."},{"key":"10.1016\/j.medcli.2025.106939_bib0485","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","article-title":"Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis","volume":"2","author":"Cheng","year":"2020","journal-title":"JACC CardioOncology."},{"key":"10.1016\/j.medcli.2025.106939_bib0675","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1182\/blood-2017-12-819904","article-title":"Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis","volume":"131","author":"Kastritis","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.106939_bib0680","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/ajh.24001","article-title":"Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T","volume":"90","author":"Dispenzieri","year":"2015","journal-title":"Am J Hematol."},{"key":"10.1016\/j.medcli.2025.106939_bib0685","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3109\/13506129.2011.627069","article-title":"Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis","volume":"18","author":"Palladini","year":"2011","journal-title":"Amyloid."},{"key":"10.1016\/j.medcli.2025.106939_bib0690","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2016-02-702696","article-title":"Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis","volume":"128","author":"Kastritis","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2025.106939_bib0510","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12883-017-0948-5","article-title":"Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy","volume":"17","author":"Adams","year":"2017","journal-title":"BMC Neurol."},{"key":"10.1016\/j.medcli.2025.106939_bib0515","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/13506129.2020.1815696","article-title":"Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis","volume":"28","author":"Louwsma","year":"2021","journal-title":"Amyloid [Internet]."},{"issue":"1-2","key":"10.1016\/j.medcli.2025.106939_bib0520","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jns.2005.03.015","article-title":"Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss","volume":"233","author":"Petzold","year":"2005","journal-title":"J Neurol Sci."},{"key":"10.1016\/j.medcli.2025.106939_bib0525","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat Rev Neurol [Internet]."},{"key":"10.1016\/j.medcli.2025.106939_bib0530","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1212\/WNL.0000000000004932","article-title":"Plasma neurofilament light chain concentration in the inherited peripheral neuropathies","volume":"90","author":"Sandelius","year":"2018","journal-title":"Neurology."},{"key":"10.1016\/j.medcli.2025.106939_bib0535","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/jns.12350","article-title":"Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis","volume":"24","author":"Kapoor","year":"2019","journal-title":"J Peripher Nerv Syst."},{"key":"10.1016\/j.medcli.2025.106939_bib0540","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/13506129.2019.1708716","article-title":"Plasma neurofilament light chain: An early biomarker for hereditary ATTR amyloid polyneuropathy","volume":"27","author":"Maia","year":"2020","journal-title":"Amyloid [Internet]."},{"key":"10.1016\/j.medcli.2025.106939_bib0545","doi-asserted-by":"crossref","first-page":"E412","DOI":"10.1212\/WNL.0000000000011090","article-title":"Neurofilament light chain as a biomarker of hereditary transthyretin-mediated amyloidosis","volume":"96","author":"Ticau","year":"2021","journal-title":"Neurology."},{"key":"10.1016\/j.medcli.2025.106939_bib0550","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11897-022-00570-1","article-title":"Update on disease-specific biomarkers in transthyretin cardiac amyloidosis","volume":"19","author":"Hood","year":"2022","journal-title":"Curr Heart Fail Rep."},{"key":"10.1016\/j.medcli.2025.106939_bib0555","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by ag10 in symptomatic transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.medcli.2025.106939_bib0560","first-page":"83","article-title":"Serum transthyretin levels in Swedish TTR V30M carriers","volume":"17","author":"Buxbaum","year":"2010","journal-title":"Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis."},{"key":"10.1016\/j.medcli.2025.106939_bib0565","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11897-020-00457-z","article-title":"Disease-specific biomarkers in transthyretin cardiac amyloidosis","volume":"17","author":"Hendren","year":"2020","journal-title":"Curr Heart Fail Rep."},{"key":"10.1016\/j.medcli.2025.106939_bib0570","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004000","article-title":"Use of serum transthyretin as a prognostic indicator and predictor of outcome in cardiac amyloid disease associated with wild-type transthyretin","volume":"11","author":"Hanson","year":"2018","journal-title":"Circ Heart Fail."},{"key":"10.1016\/j.medcli.2025.106939_bib0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2012.04.015","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS)","volume":"164","author":"Ruberg","year":"2012","journal-title":"Am Heart J."},{"key":"10.1016\/j.medcli.2025.106939_bib0580","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2025.106939_bib0585","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2025.106939_bib0590","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2025.106939_bib0595","first-page":"255","article-title":"Serum transthyretin levels in senile systemic amyloidosis: Effects of age, gender and ethnicity","volume":"15","author":"Buxbaum","year":"2008","journal-title":"Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis."},{"key":"10.1016\/j.medcli.2025.106939_bib0600","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1021\/cb100144v","article-title":"Retinol and retinol-binding protein stabilize transthyretin via formation of retinol transport complex","volume":"5","author":"Hyung","year":"2010","journal-title":"ACS Chem Biol."},{"key":"10.1016\/j.medcli.2025.106939_bib0605","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1515\/hmbci-2015-0019","article-title":"Is retinol binding protein 4 a link between adiposity and cancer?","volume":"23","author":"Noy","year":"2015","journal-title":"Horm Mol Biol Clin Investig."},{"key":"10.1016\/j.medcli.2025.106939_bib0610","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: A phase II multi-dose study","volume":"10","author":"Su\u00a0h","year":"2015","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.medcli.2025.106939_bib0615","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/jamacardio.2016.5864","article-title":"Identification of V122I (Val122IIe) transthyretin cardiac amyloidosis (ATTR) using serum retinol-binding protein 4 (RBP4) and a clinical prediction model","volume":"2","author":"Arvanitis","year":"2017","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.medcli.2025.106939_bib0620","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/ejhg.2015.180","article-title":"Variants in RBP4 and AR genes modulate age at onset in familial amyloid polyneuropathy (FAP ATTRV30M)","volume":"24","author":"Santos","year":"2016","journal-title":"Eur J Hum Genet."},{"key":"10.1016\/j.medcli.2025.106939_bib0625","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fphys.2019.00005","article-title":"The extracellular protein transthyretin is an oxidative stress biomarker","volume":"10","author":"Sharma","year":"2019","journal-title":"Front Physiol."},{"key":"10.1016\/j.medcli.2025.106939_bib0630","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12883-019-1369-4","article-title":"Inflammatory profiling of patients with familial amyloid polyneuropathy","volume":"19","author":"Azevedo","year":"2019","journal-title":"BMC Neurol."},{"key":"10.1016\/j.medcli.2025.106939_bib0635","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/labinvest.2013.83","article-title":"Fibroblasts endocytose and degrade transthyretin aggregates in transthyretin-related amyloidosis","volume":"93","author":"Misumi","year":"2013","journal-title":"Lab Invest."},{"key":"10.1016\/j.medcli.2025.106939_bib0640","doi-asserted-by":"crossref","first-page":"e0163944","DOI":"10.1371\/journal.pone.0163944","article-title":"Involvement of macrophages in the pathogenesis of familial amyloid polyneuropathy and efficacy of human iPS cell-derived macrophages in its treatment","volume":"11","author":"Suenaga","year":"2016","journal-title":"PLoS One."},{"key":"10.1016\/j.medcli.2025.106939_bib0645","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1021\/bi500171j","article-title":"Quantification of transthyretin kinetic stability in human plasma using subunit exchange","volume":"53","author":"Rappley","year":"2014","journal-title":"Biochemistry."},{"issue":"407.","key":"10.1016\/j.medcli.2025.106939_bib0650","article-title":"Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients","volume":"9","author":"Schonhoft","year":"2017","journal-title":"Sci Transl Med."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775325001459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775325001459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T16:15:21Z","timestamp":1749226521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775325001459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":65,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0025775325001459"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2025.106939","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarcadores en amiloidosis por transtirretina. Presente y futuro","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2025.106939","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106939"}}